Literature DB >> 16097244

[Intravenous immunoglobulin therapy].

Luc Mouthon1.   

Abstract

Intravenous immunoglobulins (IVIg) are therapeutic preparations of normal human IgG that are obtained from pools of healthy blood donors. They can be used at low dose in the substitutive therapy of patients with primary or secondary immune deficiencies, or at high dose as an immunomodulatory agent in a large number of autoimmune and/or systemic inflammatory diseases, particularly in hematologic or neurologic diseases. Tolerance to IVIg is excellent in most of the cases and the risk of transmission of an infectious agent is only theoretical. Mechanisms of action of IVIg are multiple and complicated. The development of new therapeutic trials in association with analyses of mechanisms of action should help to define new indication of IVIg therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16097244

Source DB:  PubMed          Journal:  Rev Prat        ISSN: 0035-2640


  2 in total

Review 1.  Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential.

Authors:  Larissa M Alvarenga; Muhammad Zahid; Anne di Tommaso; Matthieu O Juste; Nicolas Aubrey; Philippe Billiald; Julien Muzard
Journal:  Toxins (Basel)       Date:  2014-08-21       Impact factor: 4.546

2.  Analysis of the sputum and inflammatory alterations of the airways in patients with common variable immunodeficiency and bronchiectasis.

Authors:  Andrea Cristina Pereira; Cristina M Kokron; Beatriz Mangueira Saraiva Romagnolo; Claudia Simeire Albertini Yagi; Paulo Hilário Nascimento Saldiva; Geraldo Lorenzi Filho; Elnara Marcia Negri
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.